The European pharma industry experienced a 33% drop in new job postings in Q3 2023 compared with the previous quarter, with the highest share accounted for by Novo Nordisk with 2,084 job postings, according to GlobalData’s analysis of pharma company job postings. GlobalData’s Pharma: Hiring Trends & Signals Q3 2023 report reveals comprehensive insights into hiring patterns, job roles, required skills, geographical trends, and key themes within the pharmaceuticals industry, facilitating anticipation of future workforce needs. Buy the report here.
Notably, Management Occupations jobs accounted for a 16% share of the European pharma industry’s total new job postings in Q3 2023, drop 39% over the prior quarter.
Management Occupations drive pharma industry hiring activity
Management Occupations, with a share of 16% new job postings, was the occupation with the greatest hiring activity in the European pharma industry in Q3 2023 , ahead of Business and Financial Operations Occupations with a 6% share of new job postings.
The other prominent roles included Life, Physical, and Social Science Occupations with a 6% share in Q3 2023, Healthcare Practitioners and Technical Occupations with a 5% share and Computer and Mathematical Occupations with a 5% share of new job postings.
Top five companies accounted for 39% of hiring activity
Novo Nordisk posted 2,084 jobs in Q3 2023 and registered a decline of 20% over the previous quarter, followed by Novartis with 1,387 jobs and a 50% drop. AstraZeneca, with 1,090 jobs, and ICON, with 960 jobs, recorded a 13% drop and a 39% drop, respectively, while F. Hoffmann-La Roche recorded a 25% decline with a 920 new job postings during Q3 2023.
Regional analysis of hiring in the European pharma industry, Q3 2023
Germany held the leading share of the European pharma hiring activity with a 16.94% share, a 51% decrease over Q2 2023. Denmark was next with 11.90%, four-percentage-point down over the previous quarter.
For further understanding of GlobalData's Pharma: Hiring Trends & Signals Q3 2023, buy the report here.